An interventional study of Topefilgrastim Injection and Topefilgrastim Injection in Preeclampsia, sponsored by Fang Wang. Not yet recruiting at 1 site in China. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-02-03.
Sponsored by Fang Wang · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Pre-Eclampsia with a site in China — 12 open to participants now, 13 under way, 2 of them phase 3. Pre-Eclampsia · China.
Among the 36 studies in Pre-Eclampsia with a site in China, this one is the 13th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2026, is one of 12 with no phase, reaches primary completion later than 7 of the 12 other live ones, and was the 36th registered.
918 studies on the registry are indexed under Pre-Eclampsia; 243 are open to participants now.
Browse Pre-Eclampsia studies →12 of the 36 studies in Pre-Eclampsia with a site in China are open now. Recruiting first, the newest first:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Sites in China
Ages 22–40 · Women only
FANG HE · Sites in China
Ages 18–45 · Women only
Peking University Third Hospital · Sites in China
Ages 18–45 · Women only · Healthy volunteers
General Hospital of Ningxia Medical University · Sites in China
Ages 18–45 · Women only
FANG HE · Sites in China
Ages 18–45 · Women only
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 160 Pre-Eclampsia studies recruiting now, 79 (49%) set no upper age limit and 80 (50%) stop at 75 or younger; 18 take children under 18; 59 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2013; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is close to the median of 110 across 482 interventional studies indexed under Pre-Eclampsia.
Median enrollment 180 across the 19 interventional studies, 1,000 across the 17 observational. Of the 13 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 36 have an industry lead sponsor. The 10 most frequent:
Fang Wang is the lead sponsor of 4 studies on the registry; 3 are open to participants now.
Fang Wang has 1 study filed under Pre-Eclampsia — fewer than ten, so there is no comparison to draw.
3 of the studies in Pre-Eclampsia with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06414655Peking University Third HospitalMulticenter Prospective Cohort Study of Twin Maternal-Child Dyads in China | 2026-11-30 |
| NCT07384936Fang WangTopefilgrastim Injection in the Treatment of High-Risk Pregnant Patients With Preeclampsia | 2027-05 |
| NCT06821685The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolAutologous Decidual-like Natural Killer Cells Therapy for Infertility or Adverse Pregnancy History | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies in Pre-Eclampsia with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study is an open-label, prospective investigation designed to enroll 100 high-risk pregnant subjects with preeclampsia (PE). Participants will be allocated in a 2:2:1 ratio to one of three groups: the Topefilgrastim 0.5mg/biweekly group, the Topefilgrastim 1mg/biweekly group, or the control group, based on investigator judgment and patient preference. The overall study consists of three parts: a screening period, a treatment period, and a follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A risk value of ≥1/100 based on the simplified Fetal Medicine Foundation (FMF) model, OR A high-risk result from serum biomarker screening (sFlt-1, PLGF, sFlt-1/PLGF ratio). (See Appendix for details)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Topefilgrastim Injection
Drug: Topefilgrastim Injection
Subjects will receive subcutaneous injection of 0.5 mg Topefilgrastim starting from Week 1 Day 1 (W1D1), with a frequency of once every two weeks, for at least 8 consecutive weeks.
Subjects will receive subcutaneous injection of 1 mg Topefilgrastim starting from Week 1 Day 1 (W1D1), with a frequency of once every two weeks, for at least 8 consecutive weeks.
soluble fms-like tyrosine kinase-1(sFlt-1)
Time frame: Gestational weeks 11-13;15-17;24-28
placental growth factor(PLGF)
Time frame: Gestational weeks 11-13;15-17;24-28
sFlt-1/PLGF ratio
Time frame: Gestational weeks 11-13;15-17;24-28
Incidence of preeclampsia
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Incidence of early-onset preeclampsia
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Incidence of PE-associated Preterm Delivery
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Miscarriage rate
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Preterm birth rate
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Gestational age at delivery
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Neonatal birth weight
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Incidence of small for gestational age (SGA) neonates
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Admission rate to the neonatal ward
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
NICU admission rate
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Adverse Events (AEs)
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Serious Adverse Events (SAEs)
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Frequency of Adverse Events
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Frequency of Serious Adverse Events
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Severity of Adverse Events
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Severity of Serious Adverse Events
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Fetal Death
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Perinatal Death
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Incidence of congenital malformations
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Body Temperature
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Pulse
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Respiratory Rate
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Blood Pressure
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Height
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Weight
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Number of Participants with Abnormal Laboratory Parameters Findings
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Number of subjects with clinically significant abnormal findings in radiological examinations
including maternal/fetal or perinatal infants
Time frame: From 11 weeks of pregnancy to 6 weeks postpartum
Resistance Index (RI) of Uterine Spiral Arteries
Time frame: Gestational weeks 11-13;15-17;24-28
Pulsatility Index (PI) of Uterine Arteries
Time frame: Gestational weeks 11-13;15-17;24-28
Systolic to Diastolic Ratio (S/D ratio) of Uterine Spiral Arteries
Time frame: Gestational weeks 11-13;15-17;24-28
Start is estimated for Jan 2026; primary completion for May 2027, 16 months later.
Of 172 non-industry interventional studies with no phase under Pre-Eclampsia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 16 months is below that.
Counting every sponsor, half of 177 studies reached it within 24 months; a quarter within 10 and three quarters within 44.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fang Wang